**In Vitro Evaluation of Acetylcholinesterase Inhibitory and Neuroprotective Activity in Commiphora species: A Comparative Study**

**PS Dhivyas, P Selvamani, S Lathas, Vasudevan Manis, Nur Syamimi Mohd Azahan**

**ABSTRACT**

**Introduction:** Herbal medicines are widely used in the therapeutic intervention that could delay the onset of neurodegenerative diseases like Alzheimer's disease. Despite intensive advancements in the field of research currently available therapeutic strategies are often limited due to their adverse effects. Hence there is a need for the search for novel compounds for effective medications to treat neurocognitive deficits. **Objective:** The present study focused on acetylcholinesterase inhibitory and neuroprotective activity of *Commiphora* species for their possible use in Alzheimer's disease. **Methods:** Phytochemical screening, TLC bioautographic and colourimetric assay was performed to quantify their acetylcholinesterase inhibitory activity of ethanolic extracts of the *Commiphora* species. The MTT assay was carried to evaluate the neuroprotective effect against the Aβ-induced cytotoxicity in SH-SY5Y cell lines. **Results:** The bark of *Commiphora berryi*, leaves of *Commiphora caudata* and *Commiphora pubescens* were found abundant in flavonoids, glycosides, steroids and terpenoids. Further, the ethanol extract of *Commiphora berryi* (65.48% ± 0.10) showed the highest acetylcholinesterase inhibitory activity. The Aβ (25-35) induced cell damage was as evidenced at a concentration of 20µM. The neuroprotective effect of the ethanol extracts was examined in neurodegenerative cells induced by Aβ (25-35). On pretreatment with plant extracts, significant improvement in cell viability was observed as 63.42 ± 2.02% (25µg/ml) for *Commiphora berryi*. The maximum percentage of in-vitro AChE inhibition and neuroprotective effect was effective in the ethanol bark extract of *Commiphora berryi*. **Conclusion:** The results are very rousing to continue the screening of more unexplored plant species could be used for the development of novel bioactive compounds to treat the many diseases, especially for Alzheimer's disease.

**Key words:** Acetylcholinesterase, Neuroprotective, *Commiphora berryi*, *Commiphora caudata*, *Commiphora pubescens*, Aβ (25-35), SH-SY5Y Cell line.

**INTRODUCTION**

Alzheimer's disease is the most common form of dementia in older people and is characterized by progressive and irreversible neurodegeneration. Neuropathologically, Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ) and the hyperphosphorylation of tau proteins found within brain cells. The current therapies approved by the Food and Drug Administration (FDA) can only relieve the psychological and behavioural symptoms of dementia associated with Alzheimer's disease but do not halt the progression of the disease. The compounds approved by the FDA for the treatment of cognitive symptoms associated with Alzheimer's disease include Memantine and Cholinesterase inhibitors such as Donepezil, Rivastigmine, and Galantamine. In the last decade, various studies have determined the effect of these agents on activities of daily living with improvement in behavioural disturbances. Some limitations associated with acetylcholinesterase inhibitors are related to several peripheral side effects, for example, nausea, diarrhoea, and vomiting. Several mechanisms have been suggested to explain the pathogenesis of Alzheimer's disease, such as "Cholinergic hypothesis" and "amyloidal formation hypothesis". Acetylcholinesterase (AChE) is the enzyme involved in the metabolic hydrolysis of acetylcholine at cholinergic synapses in the central and peripheral nervous systems. Amyloid plaques and neurofibrillary tangles are abnormal protein aggregates defining the pathologic feature of Alzheimer's disease. AChE accelerates the assembly of amyloid β peptide (Aβ) into fibrils, a possible role of the peripheral site of the enzyme. A monoclonal antibody directed against the peripheral acidic binding site of AChE inhibits the effect of the enzyme upon the amyloid formation. In-vivo studies have indicated that AChE could enhance amyloid-beta aggregation and amyloid fibril formation. When AChE was infused stereotaxically into the CA1 region of the rat hippocampus, novel plaque-like structures were formed. Phystostigmine and donepezil have been reported to inhibit AChE induced Aβ polymerisation.

In the present study, pharmacological screening of the plant extracts with antioxidant properties was...
undertaken to discover new sources that could possibly be used in the treatment of Alzheimer’s disease. Free radical reactions have been implicated in the pathology of a large number of disease conditions such as Cancer, Alzheimer's disease, Diabetes, Inflammation and several cardiovascular diseases. Commiphora berryi (Arn) Engl., Commiphora caudata (Wight & Arn) Engl. and Commiphora pubescens (Wight & Arn) Engl. are used in traditional Indian medicine to treat diverse ailment conditions. These plants belong to the family of Burseraceae. The name Commiphora is derived from the Greek words komni (means 'gum') and phero (means 'to bear'). The oleo-gum-resin  

The acetylcholinesterase inhibitory activity of extracts was performed using Ellman's assay, which was adopted by Rhee et al.  The 2.5mm Silica gel 60 F254 plates was used as a stationary phase and chloroform: methanol (9:1 v/v) was used as the mobile phase. Plant extracts were dissolved in ethanol to a concentration of 10 mg/ml, of which 3µl was spotted on the TLC plate and developed in the solvent system. After the plates were developed, enzyme inhibiting activity was detected by spraying a mixture of 1mM of acetylthiocholine iodine (ACTI) and 1mM of 5,5'-Dithiobis [2-benzoic acid] in (DTNB) in 50mM Tris-HCl buffer of pH 8. It was left to dry at room temperature for 5 min. After drying, the plates were sprayed with 3 U/ml acetylcholinesterase enzyme solution. The acetylcholinesterase inhibiting white spots were observed in the yellow background within 15 min after spraying. Such detected spots were recognized due to the hydrolysis of the substrate ACTI by acetylcholinesterase enzyme which leads to the production of thiocholine. The product thiocholine reacts with DTNB to produce 5-thio-2- nitrobenzoate and 2-nitrobenzoate-5-mercaptothiocholine.

**TLC assay**

**Quantitative evaluation of acetylcholinesterase inhibition by microplate assay**

Percentage inhibition was quantified by measuring the amount of thiocholine produced during the hydrolysisation of acetylthiocholine. It was determined by the continuous reaction of thio with DTNB. Inhibition of acetylcholinesterase enzyme activity was determined using Ellman’s colourimetric method as modified by Rhee et al. Buffer A (Tris/HCl 50mM, pH 8), buffer B (50 mM, pH 8, containing 0.1% bovine serum albumin) and buffer C (50 mM Tris–HCl, pH 8, containing 1 M NaCl and 0.02 M MgCl2.6H2O) solution was prepared. In the 96-well plate 25 μl of 15 mM AChE in water, 125 μl of buffer B and 25 μl of plant extract (0.5, 1.0, 1.5, 2, 2.5 and 3mg/ml) dissolved in ethanol and diluted in buffer A were added. Physostigmine was used as the standard at concentrations ranging from 0.005 to 0.100 mg/ml. Absorbance was measured spectrophotometrically at 405 nm every 45s, three times consecutively. After that, AChE (0.22 U/ml) was added to the wells, and the absorbance was measured five times consecutively every 45s. Any increase in absorbance due to the spontaneous hydrolysis of the substrate was corrected by subtracting the absorbance before adding the enzyme from the absorbance after adding the enzyme. The percentage of acetylcholinesterase inhibition was calculated by comparing the reaction rates of samples to the negative control (10% ethanol in solution Tris/HCl 50 mM, pH 8, considering 100% as the total activity of acetylcholinesterase). The percentage inhibition was determined using the following equation:

\[
\text{Percentage Inhibition} = \left(1 - \frac{A_{Sample}}{A_{Control}}\right) \times 100
\]

(\text{where, A Sample - Absorbance of the sample extracts. A Control - Absorbance of the blank [methanol in Buffer A (50 mM Tris–HCl, pH 8)], A Sample = Absorbance after AChE addition – Absorbance before AChE addition. A BioTek ELISA reader was used to determine the absorbance at the time of reaction. This analysis was carried out in triplicate (n = 6) to calculate the mean and standard deviation. Extract concentration providing 50% inhibition (IC50) was obtained by plotting the percentage inhibition against extract concentration. The IC50 values of the AChE inhibition were calculated using Graph Pad Prism software.)

**Cell culture**

The human neuroblastoma cell line SH-SY5Y was obtained from National Centre for Cell Science (NCCS, Pune, India). They have the properties to express human-specific proteins and protein isoforms, which are inherently absent in primary neuronal cell culture of rodents.
The neuroblastoma cell line SH-SY5Y was chosen for this study, as it is extensively used in experimental neurological studies involving the analysis of neuronal differentiation, metabolism, and function related to neurodegenerative and neuron adaptive processes, neurotoxicity and neuroprotection. These cells exhibit biochemical and functional properties of neurons. It also can proliferate effectively in culture for an extended period without contamination. Cells were maintained in culture in Ham’s F-12 supplemented with 2% heat-inactivated fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 µg/ml). Cultures were seeded into flasks containing supplemented medium and maintained at 37 °C in 5% CO2, humidified air. Stock cultures were passaged 1:4 twice weekly.

**Determination of cell viability by MTT assay**

The SH-SY5Y cells was sub-cultured, and after trypsinisation, they are seeded into 96-well plates at a seeding density of 1 × 10^4 cells/well. These seeded plates were cultured and incubated at 37°C under 5% CO2 atmosphere for 24 hours until reaching 70% confluence. The initial concentration of extracts of selected Commiphora species plants was 100 µg/ml in DMSO: PBS: Methanol (9:2:1). Extracts of Commiphora berryi, Commiphora caudata and Commiphora pubescens were serially diluted in complete culture medium to give different concentrations of (3.15, 6.25, 12.5, 25, 50, 100 µg/ml) were added to the cells to a final volume of 100 µl. The blank well was filled with conditioned medium without cells, and the control well was filled with the cells along with the conditioned medium. After 72 hours incubation, the medium in each well was replaced with 10µl of MTT (10mg/ml) and again incubated for 4 hours. After incubation, the MTT medium in each well was removed, and 100µl of DMSO was added to dissolve the formed violet formazan crystals within metabolically viable cells. This formazan production is directly proportional to the viable cell number. The plates were shacked for 20 min, and then the optical density was measured at 570 nm with a microplate reader. Wells without cells were used as blanks and were subtracted as background from each sample. Cell viability was expressed as a percentage of the control value.

**β-amyloid modulation- Optimization of the dose of Aβ25-35 to induce toxicity**

In order to evaluate the neuroprotective activity of plant extracts, Aβ25-35 dose was optimized to induce toxicity in SH-SY5Y cell lines. Dose optimization was also performed by MTT assay in six replicates. Dose level such as 2.5, 5, 10 and 20 μM was selected.

**Determination of neuroprotective effects on treatment with Aβ25-35**

The neuroprotective effect of the selected plant extracts of Commiphora species on Aβ25-35 – induced neurotoxicity was also measured by MTT Assay in SH-SY5Y cells. Aβ25-35 was reconstituted in DMSO to a concentration of 1mM. Aliquots were incubated at 37°C for 72 hours to form aggregated amyloid. During the experiment, Aβ25-35 was directly added to the culture medium to achieve a final concentration of 20 μM. Three concentrations of each of the plant extract that presented low toxicity (as determined from the tests above) were selected to assess their possible protective effects. The cells were plated as described above and pre-treated with the plant extracts for 2 hours before adding Aβ25-35 and then incubated for 72 hours. The viability of the cells was conducted according to the MTT assay method as described above. Cell viability was expressed as a percentage of the control value. Three different concentrations (6.25, 12.5, 25µg/ml) of the plant extracts that presented low toxicity on human neuroblastoma cells as assessed by the MTT assay were selected to determine the neuroprotective effects and to determine whether they could decrease the neuronal cell death induced by Aβ in SH-SY5Y cells.

**Statistical analysis**

The analysis of the data was carried out using Graph Pad Prism 5. All experiments were performed in triplicate, and the results were expressed as mean ± SD. A significant difference in the data was evaluated by performing a one-way ANOVA analysis by Dunnet’s multiple comparison tests.

**RESULTS**

**Phytochemical screening**

The preliminary qualitative phytochemical screening of ethanolic extracts of Commiphora berryi (EECB), Commiphora caudata, (EECC) and Commiphora pubescens (EECP), revealed the presence of alkaloids, flavonoids, terpenoids, steroids, tannins and along with other phytomarkers (Table 1).

**TLC bioautographic assay**

The preliminary investigation of acetylcholinesterase inhibitory activity of ethanol extracts of selected plants was determined qualitatively by the thin layer chromatography and the results are presented in Figure 1. The white spots were observed in the yellow background for the all the plant extracts tested, thus it indicated that the presence of acetylcholinesterase. The Rf values were recorded as 0.97, 0.93, and 0.96 Commiphora berryi, Commiphora caudata and Commiphora pubescens, respectively.

**Table 1: Phytochemical analysis of ethanol extracts of Commiphora species.**

<table>
<thead>
<tr>
<th>Phytoconstituents</th>
<th>EECB</th>
<th>EECC</th>
<th>EECP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkaloids</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Amino Acids</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Anthraquinones</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Flavonoids</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Glycosides</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Proteins</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Reducing Sugars</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Saponins</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Starch</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Steroids</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Tannins</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Terpenoids</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**Figure 1:** The qualitative results of the TLC bioautographic assay of acetylcholinesterase inhibition activity of the crude ethanol extracts of Commiphora Species.
Microplate assay to assess inhibition of acetylcholinesterase enzyme

The percentage of acetylcholinesterase (AChE) inhibition of the plant extracts and also standard drug physostigmine was determined at different concentrations. The percentage inhibition increases with an increase in concentration of doses in a dose dependent manner for all the plant extracts and also the standard drug. The maximum percentage AChE inhibition (65.48%) was observed for the plant extracts of Commiphora berryi at 3 mg/ml concentration when compared with physostigmine (99.72%) at 0.100 mg/ml concentration. The moderate AChE inhibition 52.61% and 62.60% were observed for the plant extracts of Commiphora caudata and Commiphora pubescens, respectively. AChE inhibition of the plant extracts to 50% i.e. IC50, for physostigmine was 2.1 μg/mL. However, the IC50 values at 2.29, 2.92, and 2.59 mg/mL were obtained for the plant extract of Commiphora berryi, Commiphora caudata and Commiphora pubescens, and respectively (Table 2).

Cell viability assay

Determination of cell viability- MTT Assay

The gradual dose-response of the SH-SY5Y cell viability for EECC, EECC, and EECP was determined. All extracts showed > 85% of viability in terms of control in lower doses, specifically at 3.15 µg/mL of concentrations. There was a slight reduction in the percentage viability at 6.25 and 12.5 µg/mL of concentrations. A gradual reduction in cell viability was observed in all plant extracts at 25 and 50 µg/mL. Minimum viability was observed at 100 µg/mL concentrations. No saturation in viability was observed in all plant extracts at 25 and 50 µg/ml. Minimum viability was observed as 63.42 ± 0.02% (25µg/mL) for Commiphora berryi, 6.25, 12.5 and 25 µg/mL concentrations were used in the study. Based on the dose optimization these doses have been selected for the further evaluation of plant extracts. Significant improvement in cell viability was observed as 63.42 ± 0.02% (25µg/mL) for Commiphora berryi, 56.49 ± 0.18% (25µg/mL) for Commiphora caudata and 59.62 ± 0.12% (12.5µg/mL) for Commiphora pubescens when compared to Aβ control group. Therefore, the present study result reveals that optimum dose may play an important factor for the pharmacological efficacy of these extracts. Among the plant extracts tested Commiphora berryi shows the highest percentage of SH-SY5Y (Figure 4).

B-Amyloid Modulation- Optimization of the dose of Aβ25-35 to induce toxicity

In order to evaluate the neuroprotective activity of plant extracts, Aβ25-35 dose was optimized to induce toxicity in SH-SY5Y cell lines. Dose level such as 2.5, 5, 10 and 20 µM was tested, decrease in cell viability was observed while increasing the concentration of Aβ and the maximum reduction (16.21%) was observed at 20 µM. Hence, in the present study, 20 µM of Aβ25-35 concentration was selected to induce the toxicity in SH-SY5Y cell (Figures 2 & 3).

Neuroprotective Effect of Plant Crude Extracts Against Aβ25-35 Induced cell Death

The in vitro neuroprotective effect of the plant extracts were examined in neurodegenerative cells induced by Aβ. Three dose levels such as 6.25, 12.5 and 25 µg/mL concentrations were used in the study. Based on the dose optimization these doses have been selected for the further evaluation of plant extracts. Significant improvement in cell viability was observed as 63.42 ± 0.02% (25µg/mL) for Commiphora berryi, 56.49 ± 0.18% (25µg/mL) for Commiphora caudata and 59.62 ± 0.12% (12.5µg/mL) for Commiphora pubescens when compared to Aβ control group. Therefore, the present study result reveals that optimum dose may play an important factor for the pharmacological efficacy of these extracts. Among the plant extracts tested Commiphora berryi shows the highest percentage of SH-SY5Y (Figure 4).

Table 2: Acetylcholinesterase inhibitory activity of the plant extracts.

<table>
<thead>
<tr>
<th>Dose (mg/mL)</th>
<th>Percentage Inhibition (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EECB</td>
</tr>
<tr>
<td>0.5 (0.005)</td>
<td>7.24 ± 0.06</td>
</tr>
<tr>
<td>1.0 (0.010)</td>
<td>15.12 ± 0.04</td>
</tr>
<tr>
<td>1.5 (0.025)</td>
<td>34.54 ± 0.11</td>
</tr>
<tr>
<td>2.0 (0.050)</td>
<td>38.41 ± 0.08</td>
</tr>
<tr>
<td>2.5 (0.075)</td>
<td>56.56 ± 0.12</td>
</tr>
<tr>
<td>3.0 (0.100)</td>
<td>65.48 ± 0.10</td>
</tr>
<tr>
<td>IC50 ± SEM (mg/mL)</td>
<td>2.29 ± 0.11</td>
</tr>
</tbody>
</table>

Values in the parenthesis indicate as concentration of standard drug, Std. Drug, Physostigmine; n=6, each value represents the mean percentage inhibition ± SE.

Table 3: Effect of selected plant extracts on SH-SY5Y cell viability measured by MTT assay.

<table>
<thead>
<tr>
<th>Conc. (µg/mL)</th>
<th>Viability (Percentage of control)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EECB</td>
</tr>
<tr>
<td>3.15</td>
<td>91.92 ± 0.82</td>
</tr>
<tr>
<td>6.25</td>
<td>89.02 ± 0.83</td>
</tr>
<tr>
<td>12.5</td>
<td>79.60 ± 0.76</td>
</tr>
<tr>
<td>25</td>
<td>73.80 ± 2.37</td>
</tr>
<tr>
<td>50</td>
<td>63.60 ± 1.80</td>
</tr>
<tr>
<td>100</td>
<td>56.08 ± 1.70</td>
</tr>
<tr>
<td>IC50 (µg/mL)</td>
<td>81.06 ± 4.40</td>
</tr>
</tbody>
</table>

Values are mean percentage inhibition ± SEM, n=6.
Figure 3: Phase contrast photomicrograph (10x) of SH-SY5Y cell viability by MTT assay.

a) SH-SY5Y Cell on day 7
b) SH-SY5Y Cell on day 21
c) SH-SY5Y Cell treated with Aβ showing reduced growth.

Figure 4: Effect of Crude Extracts on Aβ 25-35 Induced Toxicity in SH-SY5Y Cell line.

a) Viability of cell treated with Aβ + EECP
b) Viability of cell treated with Aβ + EECC
c) Viability of cell treated with Aβ + EECB

The viability of untreated control cells was defined as 100%. Results are the mean ± SEM, n = 6. ***p<0.001 between treatment versus amyloid beta, *p<0.05 between control versus amyloid beta.
DISCUSSION
The three plant species which are included in our study have been previously reported for its natural antioxidant activities. A large amount of evidence demonstrated that oxidative stress is intimately involved in age-related neurodegenerative disease. There have been a significant number of studies that examined the positive benefits of antioxidants to block the neuronal death occurring in the pathophysiology of neurological disorders. Hence the present study was mainly focused on plants with an antioxidant property, which may protect the nervous system against oxidative damage. It may also enhance their utility in the treatment of neurodegenerative diseases. Previous data suggest that treatment with methanolic extracts of Commiphora berryi decreased the level of SOD, catalase, and GPx enzymes against CCl₄-induced oxidative damage in rats, which further confirms the free radical scavenging properties. Ethanolic extracts of Commiphora caudata and Commiphora pubescens have been previously reported for its free radical scavenging activity.

The percentage AChE inhibition of standard drug physostigmine was determined at various doses of 0.005, 0.010, 0.025, 0.050, 0.075, 0.100 mg/ml. The percentage of acetylcholinesterase inhibition of all the selected plant extracts was measured at different concentrations of 0.5, 1.0, 1.5, 2.0, 2.5, and 3 mg/mL. The AChE inhibitory activity is classified according to the percentage of inhibitory activity as described by Vinutha et al. as potent inhibitors (greater than 50% inhibition), moderate inhibitors (30-50% inhibition) and weak inhibitors (below 30%). IC₅₀ value refers to the half-maximal inhibitory concentration of plant extracts where the response is reduced by half. It is used to determine the effectiveness of the acetylcholinesterase inhibitory activity of plant extracts. Plants with a higher percentage of inhibition of the enzyme had a lower IC₅₀ value. The percentage inhibition increases with an increase in the concentration of selected plant extracts in a dose-dependent manner. All the plant extracts showed maximum inhibition at the concentration of 3mg/mL. The highest percentage inhibition was near to or greater than 50%. Plant extracts that have the minimum IC₅₀ value were considered as the most potent plant extracts with acetylcholinesterase inhibitory activity. The percentage AChE inhibition of standard drug physostigmine was determined at various doses. A gradual dose-response was observed from 0.005 to 0.100 mg/mL concentration. Maximum inhibition was observed at 0.100 mg/mL concentration.

Some of the plants with reference to our selected families have been studied for AChE inhibitory properties. Similar to our results, ethanolic extract from the leaves of Canarium putatinervium, which belongs to the Burseraceae family, also exhibited good acetylcholinesterase inhibition with an IC₅₀ value of 29.53 ± 0.19 μg/mL. Additionally, resins obtained from the chloroform extract of Boswellia spicata is a plant which belongs to the genus Boswellia, which has also belongs to the Burseraceae family, has also been reported for its potent acetylcholinesterase inhibitory activity of 71% and 46% at 0.2mg/ml respectively. The active phytoconstituents present in the plants of their respective families may be necessary for the exploration of these species for potential new therapeutic drug leads.

CONCLUSION
The outcome of various experimentation leads to the conclusion that the therapeutic potential of all the plant extracts evaluated showed remarkable inhibitory activity against AChE. Furthermore, the plant extracts also reduced the effects of beta-induced neuronal cell death. Since AD needs a multitarget drug strategy for the prevention and symptomatic treatment, it is crucial to identify the active phytoconstituents useful in both assays, and the same has to be compared with the crude extract to reveal their possible synergistic interaction. Thus, further work is in isolation of specific bioactive compounds through bio-assay guided fractionation and their characterization may be necessary for the exploration of these species for potential new therapeutic drug leads.

CONFLICTS OF INTEREST
The authors declare that they have no competing interests.

ACKNOWLEDGEMENTS
This work was funded by Department of Science and Technology, Government of India to Dr.P.Selvamani, Assistant Professor, Department of Pharmaceutical Technology, Centre for Excellence in Nanobio Translational Research (CENTRE), Anna University, Bharathidasan Institute of Technology Campus, Tiruchirappalli, Tamil Nadu, India. (DST:Ref. No. NO.SR/FT/LS-41/2010 Dated 04.05.2012.) Authors would like to thank the University Grants Commission for the financial grant provided to Ms. P. S. Dhivya, Senior Research Fellow, UGC Letter No. F1-17.1/2012-13/RGNF-2012-13-SC-TAM-27613/SA-III/Website) and dated 06-Jun-2012 posted in the UGC website on 19.02.2013.

REFERENCES
### Graphical Abstract

<table>
<thead>
<tr>
<th>Plant Name</th>
<th>TLC Bioautographic Assay</th>
<th>Microplate Assay</th>
<th>Cell Line Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commiphora berum Am. (Eng.)</td>
<td>Rf value 0.97</td>
<td>IC&lt;sub&gt;50&lt;/sub&gt; 2.29±0.11</td>
<td>Evaluation of AChE inhibition by microplate assay</td>
</tr>
<tr>
<td></td>
<td></td>
<td>65.48±0.10 (3mg/mL)</td>
<td></td>
</tr>
<tr>
<td>Commiphora caudata (Wight &amp; Am.) Engl.</td>
<td>Rf value 0.93</td>
<td>IC&lt;sub&gt;50&lt;/sub&gt; 2.92±0.07</td>
<td>Effect of Aβ25-35 Induced Toxicity in SH-SY5Y Cell line</td>
</tr>
<tr>
<td></td>
<td></td>
<td>52.61±0.10 (3mg/ml)</td>
<td></td>
</tr>
<tr>
<td>C. caudata var. polystachya (Wight &amp; Am.) Matteu</td>
<td>Rf value 0.96</td>
<td>IC&lt;sub&gt;50&lt;/sub&gt; 2.59±0.51</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>62.60±0.12(3mg/ml)</td>
<td></td>
</tr>
</tbody>
</table>

### About Authors

**P.S. Dhivya**, GATE 2008 qualified and secured second rank in her Post-graduation in M.Pharm at Periyar College of Pharmaceutical Sciences, Tiruchirappalli. She was selected for JRF in DST-SERB Sponsored research project (2012-2013), later she was selected as the JRF & SRF UGC Fellowship (2013-2018) in the Department of Pharmaceutical Technology, Anna University, Tiruchirappalli. She holds a PhD in Pharmaceutical Technology from Anna University, Chennai and is a Guest Faculty in the Department of Biomedical science, Bharathidasan University, Tiruchirappalli. Her main area of research work is on Pharmacoeconomics and Neurocognitive studies.

**Dr. Palanisamy Selvamani** completed a Bachelor’s degree in Pharmacy at the Dr. M.G.R. Medical University, Chennai, a Master’s degree in Pharmaceutical Engineering and a Doctor of Philosophy in Pharmacy at Jadavpur University, Kolkata, India. Currently, Dr. Selvamani is an Associate Professor in the Department of Pharmaceutical Technology, at Anna University with 20 years of experience in academic research involved in the identification and evaluation of Phyto-drugs for Rheumatoid arthritis, Alzheimer’s disease and antimicrobial peptides from marine sources. He is a visiting scientist to Technische Universität, Ilmenau, Germany, Yokohama National University, Japan and Shizuoka University, Japan and the recipient of the 2014 Active Researcher Award of Anna University.

**Dr. Subbiah Latha** completed a Bachelor’s degree in Pharmacy at the Dr. M.G.R. Medical University, Chennai, a Master’s degree in Pharmaceutical Engineering and a Doctor of Philosophy in Pharmacy at Jadavpur University, Kolkata, India. Currently, Dr. Latha is an Associate Professor in the Department of Pharmaceutical Technology, at Anna University with 20 years of experience in academic research. She is involved in the development of novel drug carriers using magnetic nanoparticles for targeted drug delivery. She is a visiting scientist to Technische Universität, Ilmenau, Germany, Yokohama National University, Japan and Shizuoka University, Japan and the recipient of the 2014 Tamil Nadu Young Women Scientist Award.